Novavax, Inc.
(NASDAQ : NVAX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -6.57%142.710.0%$3011.86m
BIIBBiogen, Inc. 1.15%242.941.7%$683.50m
NVAXNovavax, Inc. -9.96%125.6092.9%$603.99m
AMGNAmgen, Inc. 1.49%225.361.3%$582.30m
BNTXBioNTech SE -7.53%114.890.0%$562.05m
GILDGilead Sciences, Inc. 1.14%61.361.0%$526.85m
VRTXVertex Pharmaceuticals, Inc. 0.61%229.141.9%$502.91m
REGNRegeneron Pharmaceuticals, Inc. 0.89%520.632.7%$494.29m
ILMNIllumina, Inc. 4.11%335.333.5%$392.63m
APVOAptevo Therapeutics, Inc. 0.25%43.8418.3%$242.94m
SGENSeagen Inc. 5.10%179.005.8%$184.93m
EXASEXACT Sciences Corp. 3.63%125.4519.6%$179.41m
ALXNAlexion Pharmaceuticals, Inc. -0.36%121.682.0%$148.90m
HALOHalozyme Therapeutics, Inc. 3.41%40.4418.4%$138.64m
SRNESorrento Therapeutics, Inc. -1.89%8.051.4%$137.23m

Company Profile

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.